Dr. Razani received his B.S. in Electrical Engineering and Computer Science and B.A. in Molecular and Cellular Biology from the University of California at Berkeley. He then went on to earn M.D. and Ph.D. degrees as part of the MSTP at Albert Einstein College of Medicine.  After completing Internal Medicine residency and Cardiovascular fellowship at Washington University School of Medicine, he stayed on as faculty rising to the rank of Associate Professor with tenure. In 2022, he moved his clinical and research operations to Pittsburgh where he currently serves as the Chief of Cardiology at the Pittsburgh VA Medical Center and Professor of Medicine and Director of the Center for Immunometabolism at the University of Pittsburgh School of Medicine.

A committed physician-scientist, Dr. Razani has remained active as a clinical cardiologist while running a large research lab conducting seminal work in the atherosclerosis and metabolism fields. He was the first to establish that the autophagy-lysosome system becomes dysfunctional in atherosclerosis and described the pathogenic relevance of cytotoxic protein aggregates that accumulate as a result. His work on stimulating the transcription factor TFEB as a means of driving autophagy-lysosomal biogenesis shows the potential power of this pathway in ameliorating cardiovascular and cardiometabolic diseases. Dr. Razani is currently funded by a VA MERIT award and 3 NIH R01 awards from the NHLBI and NIDDK and his research has led to publications in premier journals including Circulation Research, Cell Metabolism, and Nature Metabolism. Dr. Razani’s efforts have been recognized by the scientific community receiving prestigious honors at national forums including the Irvine Page (ATVB), David Williams (Kern), and Springer (NAVBO).